Anthracyclines are among the most effective chemotherapeutic agents used to treat pediatric malignancies.
However, their clinical use is limited by dose-dependent toxicities, particularly cardiotoxicity and secondary malignancies.
Aclarubicin (Acla) is an anthracycline derivative that induces chromatin damage while sparing DNA, offering potential therapeutic benefit with reduced longterm toxicity.
